Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention.

Jordi Esteve,Lourdes Escoda,G. Martin,Viñas Rubio,Joaquín Díaz-Mediavilla,Marcela González,Concha Rivas,Concepción Luján-Álvarez,J D González San Miguel,Salut Brunet,Jf Tomás,M. Tormo,Sayas Mj,P Sánchez Godoy,Dolors Colomer,Pascual Bolufer,Miguel A. Sanz

Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention.

2007

Jordi Esteve
Lourdes Escoda
G. Martin
Viñas Rubio
Joaquín Díaz-Mediavilla
Marcela González
Concha Rivas
Concepción Luján-Álvarez
J D González San Miguel
Salut Brunet
Jf Tomás
M. Tormo
Sayas Mj
P Sánchez Godoy
Dolors Colomer
Pascual Bolufer
Miguel A. Sanz

Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all- trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention

Keywords:

Oncology
Cancer research
Hematology
Anthracycline
Acute promyelocytic leukemia
Retinoid
Tretinoin
Surgery
Medicine
Internal medicine
Salvage therapy
Chemotherapy
Retinoic acid
Transplantation

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations